What Are the Best Practices for Managing Incidental Pulmonary Nodules Detected During Lung Cancer Screening?

A patient comes in for lung cancer screening. The scan is reviewed, and somewhere in the report, there it is - a pulmonary nodule.

Sometimes it’s expected. Sometimes it’s not.

The question is rarely "what is this?"
The real questions is "what do i do with this now?"

Most nodules are benign. But a small number represent early malignancy, and those are the ones that matter. The challenge is not just identifying nodules, it’s deciding which ones require action and which ones can be safely followed.

That’s where variability starts to creep in.

On paper, nodule management seems straightforward. Guidelines exist. Thresholds are defined. Follow-up intervals are published.

In practice, things are less clear.

A 5 mm nodule in one patient may be low risk.
The same nodule in another patient may not be.

Growth may be subtle. Measurements may vary. Prior imaging may not be easily accessible. And sometimes, what is written in the report doesn’t fully translate into a clear plan.

That’s why managing incidental nodules during screening is less about memorizing thresholds and more about applying consistent clinical reasoning.

Most clinicians rely on Lung-RADS within screening programs and Fleischner guidelines for incidental findings outside of them.

These frameworks are essential. They provide structure and reduce unnecessary variation.

But they are starting points, not endpoints.

Guidelines tell you:

They don’t replace clinical judgment.

Nodule size is often the first thing we look at.

Small nodules, particularly those under 6 mm, are usually low risk. Larger nodules require more structured follow-up. But size alone is not enough.

What matters just as much is:

Two nodules of the same size can behave very differently. That’s why management decisions need to be contextual, not formulaic.

If there is one principle that consistently guides nodule management, it is this:

A single scan provides a snapshot.
Serial imaging provides a pattern.

Stability over time generally suggests benign disease.
Growth, even subtle, changes the equation.

This is why follow-up intervals matter so much. Not just whether follow-up happens, but when it happens.

Too early, and you may not see meaningful change.
Too late, and you risk delaying diagnosis.

Subsolid nodules often require a different approach than solid nodules.

They tend to:

This means follow-up may extend over years, not months.

Recognizing these differences is essential. Applying a single approach to all nodules leads to either over-management or missed risk.

Most nodules will remain under surveillance.

But certain changes should prompt escalation:

At that point, the question shifts from “should we follow this?” to “should we intervene?”

This is where multidisciplinary input becomes important.
Decisions around PET imaging, biopsy, or surgical evaluation are rarely made in isolation.

Even with guidelines, variability remains a reality.

It often comes from:

These are not knowledge gaps.
They are execution gaps.

And they can change patient outcomes.

Management decisions are only as effective as their follow-through.

Even when the right recommendation is made, it still depends on:

Studies have shown that a significant proportion of patients with pulmonary nodules do not complete recommended follow-up (Wiener et al., 2013).

This is where clinical decision-making meets system design.

At a practical level, managing incidental nodules well comes down to a few principles:

Each of these steps is straightforward in isolation.
The challenge is maintaining consistency across all of them.

As screening programs expand, the number of nodules requiring follow-up continues to grow.

At that scale, management becomes less about individual decisions and more about system reliability.

Maintaining visibility across patients, ensuring follow-up over time, and coordinating across teams requires infrastructure.

Platforms such as qTrack are designed to support this layer, helping track patients identified through both screening and incidental findings and ensuring that recommended follow-up is completed. qTrack creates accountability for every nodule and helps ensure that less to no patients fall through the cracks.

This allows clinical teams to focus on decision-making, while reducing the risk that patients fall out of the pathway.